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Abstract
Background: Statins have long been used as anti-hypercholesterolemia drugs, but numerous lines of evidence
suggest that they may also bear anti-tumour potential. We have recently demonstrated that it was possible to
isolate cancer cells adapted to growth in the continuous presence of lovastatin. These cells grew more slowly than
the statin-sensitive cells of origin. In the present study, we compared the ability of both statin-sensitive and statin-
resistant cells to give rise to tumours in Nude mice.
Methods: HGT-1 human gastric cancer cells and L50 statin-resistant derivatives were injected subcutaneously into
Nude mice and tumour growth was recorded. At the end of the experiment, tumours were recovered and marker
proteins were analyzed by western blotting, RT-PCR and immunohistochemistry.
Results: L50 tumours grew more slowly, showed a strong decrease in cyclin B1, over-expressed collagen IV, and
had reduced laminin 332, VEGF and CD34 levels, which, collectively, may have restricted cell division, cell adhesion
and neoangiogenesis.
Conclusions: Taken together, these results showed that statin-resistant cells developed into smaller tumours than
statin-sensitive cells. This may be reflective of the cancer restricting activity of statins in humans, as suggested from
several retrospective studies with subjects undergoing statin therapy for several years.
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Background
Statins are widely used anti-hypercholesterolemia drugs
and act through competitive inhibition of HMG-CoA
reductase, the first enzyme controlling entry into the
mevalonate pathway that leads, ultimately, to cholesterol
and steroid hormone synthesis [1]. This drug family
comprises both natural (lovastatin, simvastatin, pravasta-
tin) and synthetic (fluvastatin, atorvastatin) molecules
that efficiently lower LDL cholesterol levels [2]. Apart
from their role in the control of cholesterol homeostasis,
statins have been proposed to lower cancer incidence in
several large trials, for colon, breast and lung cancers,
among others [3,4]. However, other large trials have not
confirmed this potential chemo-preventive effect [5].
The origin of the differences is not known, but a recent
study indicated that these might partly depend on the
particular allelic form of the HMGCR gene (encoding
HMG-CoA reductase), as an alternative pre-mRNA spli-
cing event - associated with a specific SNP genotype -
leads to differences in the activity of the enzyme [6].
In addition to this cancer prevention potential, statins
have long been known to trigger apoptosis in many cell
culture models, to prevent or reduce tumour occurrence
in animals or to reduce the incidence of metastases [7].
The tumour suppressive effect has been proposed to
rely partly on the ability of statins to block production
of farnesyl pyrophosphate or geranyl-geranyl pyropho-
sphate, which provide target proteins with C15 or C20
post-translational carbon chain additions that help sig-
nalling molecules like Ras or Rho anchor to the plasma
membrane and drive cell proliferation [8,9]. Cholesterol
deprivation might also hamper tumour cell proliferation
by restricting the ability to renew membrane pools.
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One question that arises is what would happen, in the
apoptotic response, if the sensitivity of the cells to sta-
tins was reduced, either as an intrinsic or an acquired
phenotype following long periods of drug intake? To
address this question, we isolated a population of statin-
resistant cells, which we named L50, that was stably
resistant to a relatively high concentration of statins in
culture (50 μM), derived from the human gastric cancer
HGT-1 cell line [11]. These cells showed increased
expression of pro-caspase-7, that we further showed to
be under the positive control of SREBP-1 and SREBP-2
proteins, much like proteins from the mevalonate path-
way and pro-caspase-2 [12]. In vitro growth of HGT-1
and L50 cells showed that the latter had a reduced
growth rate, suggesting that, should intrinsic resistance
to statins occur, it would not be associated with
increased growth. The aim of the present study was to
investigate cell growth parameters and marker gene
expression in tumours developed in Nude mice from
HGT-1 or L50 cells.
Our results showed that tumour growth was slower in
L50 than in HGT-1 tumours, as found for cells grown
in vitro. In addition, the over-expression of caspase-7 in
L50 vs HGT-1 cells was maintained in tumours, further
demonstrating phenotype stability. The lower growth of
L50 tumours was associated with a strong reduction in
cyclin B1. In addition, these L50 tumours showed over-
expression of collagen IV, and reduced laminin 332,
VEGF and CD34 levels, which may have restricted cell
adhesion and neoangiogenesis. Taken together, these
results suggest that adaptation to statins led to impor-
tant phenotype modifications, which, collectively, con-
ferred a reduced ability of tumour cells to grow in
immuno-compromised mice.
Methods
Cell culture
HGT-1 human gastric cancer cells and HGT-1-derived
L50 cells were grown at 37°C under a humidified
atmosphere of 5% CO2 in DMEM (Dulbecco’sm o d i -
fied Eagle’s medium) (Lonza, Saint Beauzire, France),
containing 4.5 g.L
-1 glucose and supplemented with 5%
(v/v) foetal bovine serum without antibiotics (Gibco-
Invitrogen, Cergy Pontoise, France) [11,13]. L50 cells
had been selected following several weeks of perma-
nent growth in presence of 50 μM lovastatin. Cell
death no longer occurred after that period and pheno-
type stability was ascertained over several cell passages
in the absence of lovastatin [11]. HGT-1 and L50 cells
were grown and used for injection into Nude mice (see
below).
Tumour induction in Nude mice
Twenty healthy female Balb/c Nude mice (4 weeks-old)
were obtained from Charles River (L’Arbresle, France).
Animals were maintained for 7 days in a conventional
animal care unit before the start of the study (INSERM
U 6 2 5 ,R e n n e s ,F r a n c e ,A g r e e m e n tN o .4 0 1 6f r o mt h e
French Ministries of Agriculture and Research). Animal
experiments were performed according to ethical guide-
lines of animal experimentations.
Before cell injection, the mi c ew e r ea n e s t h e t i s e db y
intra-peritoneal injection of pentobarbital (70 mg/kg;
Sigma, France). The cells (2 × 10
7 cells/mouse in 200 μl
of serum-free medium) were then inoculated by subcu-
taneous injection in the right flank of each mouse (10
mice per group). After cell inoculation, mice were
observed for 2 h post-injection to ascertain that no
health condition occurred. Tumour growth was followed
during 31 days. The tumor volume was calculated
according to the formula: (length × width
2)/2 [14]. Ran-
domization all along the covered period, including ran-
domization to affect animals to the treatment groups, to
pick up the mice from both groups and to measure the
tumour volumes was used for all the experiment. At the
end of this period, the mice were sacrificed and tumours
were recovered for analysis.
Protein extraction and western blotting analysis
Frozen tumours were rapidly homogenised in Phosphate
Buffered Saline (PBS) and lysed in ripa buffer (50 mM
Tris HCl pH7.4, 150 mM NaCl, 0.5% (wt/v) Sodium
deoxycholate, 0.1% SDS, 1% NP40, 1 mM EDTA, 1 mM
PMSF) containing protease inhibitor cocktail (Roche,
Meylan, France) and phosphatase inhibitor (Active
motif) for 10 min at 4°C. Sixty micrograms of proteins
were boiled in Laemmli buffer for 5 min, separated by
SDS-PAGE using 12% or 15% polyacrylamide gels and
blotted onto polyvinyl difluoride membranes (GE
Healthcare). Non specific binding sites were blocked for
1 h at room temperature by 5% (wt/v) fat-free milk
before an overnight incubation at 4°C with specific rab-
bit anti-human antibodies: procaspase-3, -6, -7 or -9,
aurora kinase A and B, Bcl-2, Bax and survivin (Cell Sig-
nalling Technology-Ozyme, Saint Quentin en Yvelines,
France), p21, Mcl-1 and cyclin B1 (Santa Cruz biotech-
nology, Tebu-bio, le Perray en Yvelines, France), cyclin
D1 (NeoMarkers, Thermo Fisher Scientific, Illkirch,
France) or HSC70 (Abcam, Paris, France) as a loading
control. Primary antibodies were detected with a horse-
radish peroxidase-conjugated donkey anti-rabbit IgGs
(GE Healthcare, Orsay, France). Blots were revealed
using an Enhanced Chemiluminescence detection kit
(GE Healthcare) and analyzed with the Chemcapt™
software.
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In situ analyses of structural proteins were performed as
previously reported [15]. Antibodies sources were as fol-
lows: laminins 332 and 111 (gifts of Dr Patricia Rous-
selle, CNRS, Lyon), E-Cadherin (Zymed, USA), CD34
(Becton-Dickinson, USA), EGFR/c-erbB-2 (Zymed,
USA), MMP7 (Chemicon International Inc. USA), col-
lagen IV (Chemicon International Inc. USA).
Fixed frozen 7 mm tissue sections were rehydrated
with 10% Fetal Calf Serum/PBS for 10 min. After several
PBS washes, sections were incubated for 60 min. with
the specific antibodies, washed in PBS and incubated for
30 min. with TRITC- or FITC-conjugated secondary
antibodies. After two PBS washes, sections were
mounted with fluorescent mounting medium (DAKO)
and analyzed with a Nikon Eclips 80i fluorescence
microscope. Slides were analyzed following randomiza-
tion. The labelling analysis was performed blindly, and
the tissue sections (serial sections) were exposed blindly
to the antibodies and read by two independent observers
with at least 20 microscopic fields per condition.
RNA extraction and RT-PCR analysis
Total RNA was isolated using Trizol (Invitrogen, Cergy-
Pontoise, France) and the RNA samples were used for
the first-strand cDNA synthesis with the High Capacity
cDNA Reverse Transcription kit and random hexamer
primers (Applied biosystems). Quantitative real-time
RT-PCR was performed using the Power SYBR Green
Kit (Applied biosystems) according to the manufac-
turer’s instructions. mRNA levels were analyzed in
duplicate and normalized to GAPDH mRNA as an
internal control. The primer sequences and reaction
conditions will be provided upon request.
Results and discussion
1-Statin-resistant cells grow more slowly in Nude mice
We have previously shown that L50 cells had a slower
growth rate in vitro than HGT-1 cells [11]. To deter-
mine if this was also the case in vivo,w ei n j e c t e dNude
mice with either cell populat i o na n da n a l y s e dt u m o u r
volumes up to 31 days post-implantation. As can be
seen from Figure 1, HGT-1 tumours were readily
detected after 13 days, whereas it required several more
days for L50 tumours to become detectable. The slope
of the growth curve was lower all along for L50 cells. At
the end of the growth period, the mean tumour volume
was 2.5 times higher for HGT-1 than for L50, with an
average doubling time of 21.7 ± 5.12 days for HGT-1
cells and 25.30 ± 9.38 days for L50 cells. This difference
in growth rates was statistically significant (P<0.05).
These results demonstrate that statin-adapted cells had
a slower growth rate in vivo, as they did in vitro. Never-
theless, the ability to form tumours was not impaired in
L50 cells since as many mice (10 animals per group)
developed tumours for both cell populations.
Expression of lipid metabolism and transport genes
was reduced in L50 tumours, except for SREBP-2 that
was expressed at similar levels in both tumour types
(Table 1).
2-Marker expression in HGT-1 and L50 tumours
To look for potential differences in marker proteins
between HGT-1 and L50 tumours, we conducted a wes-
tern blotting analysis. As shown in Figure 2a, pro-cas-
pase-3 and pro-caspase-7 protein levels were higher in
L50 tumours, albeit only slightly for pro-caspase 3, as
had been seen in L50 cells in culture [11]. Similarly, a
3.9-fold and 1.5-fold over-expression of caspase-7 and
caspase-3 mRNA levels, respectively, were also observed
(Table 1). Pro-caspase-6 and procaspase-9 proteins were
roughly unchanged (Figure 2a). Caspase-9 mRNA level
showed no change, and caspase 6 mRNA was only mar-
ginally increased (Table 1). Both Bax and Bcl-2 protein
levels were slightly raised in L50 tumours (Figure 2b),
whereas Bcl-2 expression was really difficult to detect in
HGT-1 and L50 cells in culture, suggesting that the
reactivation of this gene was essential to allow both
types of cells to develop into tumours. Bax and Bcl-2
mRNA were raised in L50 tumours (Table 1). Interest-
ingly, increased expression of these two proteins has
been shown in human gastric cancer samples [17]. In
addition, an over-expression of Bcl-2 has been detected
in low grade and early stage of gastric carcinomas [18].
The anti-apoptotic form of Mcl-1 was strongly raised
in L50 tumours. Because L50 cells grown in vitro also
showed higher levels of the Mcl-1 protein (data not
shown), this can be interpreted as an anti-apoptotic
adaptive response to growth in the continuous presence
of statins during the in vitro selection procedure, a trait
that was maintained in vivo. Although a high level of
Mcl-1 expression was associated with a poor prognosis
for many cancer types [19], its over-expression in L50
tumours might not be relevant with respect to growth
potential, which clearly is a distinct endpoint from the
survival of individuals who have gone through rounds of
anticancer therapies. Mcl-1 mRNA levels were not
raised in L50 cells (Table 1), indicating a possible stabili-
zation event for the protein. Survivin levels were very
low and comparable between both tumour types.
We next looked at the expression of proteins involved
in the control of cell division. As can be seen in Figure
2c, the levels of cyclin D1, p21 and aurora kinases A &
B proteins were not different between HGT-1 and L50
tumours. Strikingly, however, L50 tumours showed a
strong decrease in the level of cyclin B1, as compared to
HGT-1 tumours. In fact, over-expression of cyclin B1
has been positively correlated to grade, higher
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and invasiveness in breast, prostate and thyroid malig-
nant lesions [20-22]. Consequently, the reduction of
cyclin B1 in L50 cells might have conferred the cells a
restricted proliferation potential. Cyclin B1 mRNA level
was also decreased (Table 1).
Taken together, these results indicate that the slower
growth of L50 tumours, as compared to HGT-1
tumours, may be attributed to a reduced activity of cell
division, possibly under the control of cyclin B1.
3-In situ marker analysis
To analyse the relationship between tumour growth and
the tumour environment, we next looked at the expres-
sion of extracellular matrix proteins, cellular junctions
and neoangiogenesis markers by immunohistochemistry
on serial sections prepared from HGT-1 and L50
tumours.
Morphology analysis showed that HGT-1 tumours
were less differentiated than L50 cells, which also
appeared more rounded. In addition, L50 tumours
showed a lobular structure, which was not observed in
HGT-1 tumours (Figure 3).
The extracellular matrix protein laminin 332 was less
expressed in L50 than in HGT-1 tumours, whereas the
reverse was true for collagen IV (Table 2). All the
tumours expressed Laminin 332, but its localization was
variable between tumour types: it was localized between
the vessels of HGT-1 tumours and in the cell cytoplasm
and intercellular spaces in L50 tumours, but at rather
Figure 1 Tumour induction in Nude mice.H G T - 1o rL 5 0c e l l sw e r ei n j e cted (subcutaneously) to Nude mice and tumour volumes were
recorded as a function of time post-implantation (see Methods). Values are means ± S.D. (n = 10). * Statistical significance was set at the level of
5% (Student’s t test).
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similar levels in both tumours. Nevertheless, since lami-
nin 111 is never produced by epithelial cells, we may
speculate that the observed laminin 111 staining could
have been contributed by other cells. Collagen IV stain-
ing was more marked in L50 than in HGT-1 tumours
(Table 2), namely at the level of blood vessels. In
addition, a few cells, probably fibroblasts, expressed col-
lagen IV in the conjunctive tissue space.
E-cadherin, an epithelial and endothelial cell junction
marker, which abnormal expression has been implicated
in hereditary forms of gastric cancer [23], did not dis-
play obvious differences between HGT-1 and L50
tumours, but was well expressed by the host vessels.
The neoangiogenesis CD34 marker appeared more
expressed by HGT-1 tumours (Table 2), which supports
the notion that angiogenesis was more active in HGT-1
than L50 tumours and, presumably, could have contrib-
uted to the higher growth rate of HGT-1 tumours when
compared with L50 tumours. In addition, VEGF was
strongly expressed in HGT-1 tumours but was barely
detectable in L50 tumours (Figure 3 & Table 2).
c-erbB-2, a receptor tyrosine kinase member of the
EGFR family, involved in growth control, cell adhesion,
migration and differentiation, was obviously expressed
by stromal cells between tumour islets. In addition, L50
tumours appeared to express more c-erbB-2 than HGT-
1 tumours (Table 2).
Matrilysin 1 (MMP7), which is generally strongly
involved in the proteolytic process of the stroma,
appeared more expressed by L50 than by HGT-1
tumours at the cell level. This may seem contradictory,
as the consequence of such over-expression should be
increased metastatic potential for L50 cells. Neverthe-
less, we obtained no evidence for metastases in the
course of this study. It may be possible that the thresh-
old level for tumour cells to evade from the tumour and
form metastases was not attained.
To summarize, when compared to HGT-1 tumours,
L50 tumours displayed over-expression of collagen IV,
c-erbB-2 and MMP7, and reduced laminin 332, CD34
Table 1 RT-PCR analysis of marker gene expression in
L50 tumour samples compared to HGT-1 tumours
Lipids synthesis HMG-CoA reductase 0.7 ± 0.1*
SREBP-1 0.6 ± 0.2*
SREBP-2 n.c.
LDL receptor 0.3 ± 0.06***
FAS 0.6 ± 0.1**
Cell proliferation Cyclin D1 0.7 ± 0.2***
Cyclin B1 0.66 ± 0.3*
P21 n.c.
EGFR n.c.
Apoptosis Caspase 2 n.c.
Caspase 3 1.5 ± 0.4**
Caspase 6 1.3 ± 0.2**
Caspase 7 3.9 ± 0.6***
Caspase 9 n.c.
Bax 1.3 ± 0.3*
Bcl2 1.6 ± 0.4**
Mcl-1 n.c.
Real Time RT-PCR was performed with mRNA samples extracted from 10
tumours from independent mice. The fold variation was determined with the
ΔΔCt method [16]. HGT-1 mRNA levels were set to 1. The mRNA levels in L50
tumours were expressed relative to those in HGT-1 tumours. * Statistical
difference (p < 0.05); ** Statistical difference (p < 0.01); *** Statistical
difference (p < 0.001) (Student’s t test) n.c. no change
Figure 2 Western blot analysis in HGT-1 and L50 tumours in Nude mice. Marker protein expression was analysed by western blot in
tumours from Nude mice, 31 days after implantation. Protein samples were prepared from pools of 6-8 mice per group. Protein levels were
standardized to those of HSC-70. The data are from one experiment representative of at least three independent experiments with similar results.
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tion in L50 tumour growth may be largely explained by
a more differentiated phenotype, and a reduced ability
to undergo tumour neo-angiogenesis. Hence, it can be
hypothesized that gastric cancers developed in indivi-
duals with a long history of statin treatment, might be
more responsive to targeted chemotherapy including
trastuzumab or lapatinib, c-erbB-2 inhibitors, which
anticancer potentials are currently being evaluated in
several clinical trials [24].F r o ma ne x p e r i m e n t a lp e r -
spective, we plan to develop a large-scale proteomic
approach with the aim of identifying additional markers
that could also participate in the reduction of growth
potential for statin resistant cells in vivo.T h i st y p eo f
approach has been recently developed [25] with breast
cancer cells in vitro following treatment with lovastatin,
but we are not aware of any study that would have ana-
lyzed the proteome of cells selected for their resistance
to statins. Interestingly, no overlap between our results
and those from this analysis was observed. Although
this may in part be due to the difference in cell types
(breast vs stomach), we surmise that the situations -
short-term treatment with lovastatin or selection of
lovastatin-resistant cells - may not be comparable at all.
Future experiments should shed new light on this
question.
Conclusion
This study showed that adaptation to the continuous
presence of statins in vitro led to a growth phenotype
that was inherited and largely maintained in tumours
formed in Nude mice. Hence, growth was reduced in
Figure 3 Histology of HGT-1 and L50 tumours. Upper panel: Representative section of HGT-1 and L50 tumours stained with hematoxylin-
eosin (Original magnification × 200). Middle and lower panels: Immunofluorescence of HGT-1 and L50 tumours. Laminin 332 appeared more
extensively expressed in HGT-1 tumours than in L50 tumours, namely in extracellular conjunctive spaces and also in some conjunctive cells. VEGF
was well expressed in inter-tumoral spaces at the fiber and cell level. Its expression appeared stronger in HGT-1 than in L50 tumours (Original
magnification × 400)
Table 2 Semi-quantitation of protein levels from the
immunofluorescence analysis
HGT1 L50
Laminin 332 ++ +
Laminin 111 ++ ++
Collagen IV + ++
E-Cadherin + +
CD34 ++ +
VEGF ++ +/-
c-erbB-2 + ++
MMP7 + ++
A semi-quantitative analysis of fluorescence signals in tumour cells was
tabulated. Each analysis was based on the observation of at least 20
microscopy fields.
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degree of differentiation and a restricted ability to
undergo neo-angiogenesis. The elevation in the levels of
pro-caspase-3, pro-caspase-7 and Bax in L50 tumours
suggested that they might be more sensitive to antican-
cer treatments than HGT-1 tumours, since they
expressed a higher pool of pro-apoptotic molecules, pre-
sumably prone to drug-induced activation. Moreover,
that the level of cyclin B1 was lower in L50 tumours
suggests that they might be less aggressive and, possibly,
more responsive to chemotherapy, a hypothesis that we
plan to test in the future. As a model with these HGT-1
and L50 cells, it can be proposed that cancer cells that
would appear in individuals undergoing statin therapy
would be less likely to develop into tumours. Such
effects could account, in part, for the lower incidence of
several types of cancers in humans treated by statins for
several years, as has been suggested in several retrospec-
tive studies [3,4]. Future trials could help evaluate this
hypothesis through the analysis of markers in tumours
from naïve or statin-treated subjects.
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